FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

5 results

akynzeo
(Netupitant and Palonosetron)
Helsinn Therapeutics (U.S.), Inc.
Usage: AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing initial and repeat courses of highly emetogenic cancer chemotherapy, used in combination with dexamethasone. It consists of palonosetron and netupitant (or fosnetupitant in injectable form).
aponvie
(APREPITANT)
Heron Therapeutics, Inc.
Usage: APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. It is not studied for treating already established nausea and vomiting.
aprepitant
(Aprepitant)
Glenmark Pharmaceuticals Inc., USA
Usage: Aprepitant is indicated for preventing chemotherapy-induced nausea and vomiting (CINV) in patients aged 12 and older undergoing highly or moderately emetogenic chemotherapy, and for preventing postoperative nausea and vomiting (PONV) in adults. It is not intended for treating established nausea and vomiting.
cinvanti
(aprepitant)
Heron Therapeutics, Inc.
Usage: CINVANTI is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing highly and moderately emetogenic cancer chemotherapy, used in combination with other antiemetics and in specific dosing regimens. It is not studied for treating established nausea and vomiting.
varubi
(rolapitant)
TerSera Therapeutics LLC
Usage: VARUBI® is indicated for the prevention of delayed nausea and vomiting in adults undergoing emetogenic cancer chemotherapy, in combination with other antiemetic agents. This includes initial and repeat courses of highly emetogenic chemotherapy.

Substance P/Neurokinin-1 Receptor Antagonist class drugs

akynzeo

aponvie

aprepitant

cinvanti

varubi